Autologous cell therapy has been used in patients with chronic limb-threatening ischemia for many years. Numerous studies and meta-analyses assessed benefits of cell therapy and also presented its new possibilities.
In addition to the standard sources of stem cells, like bone marrow and peripheral blood, new possibilities of using various types of tissues were considered. There is still question about a comparison of the effect among different types of cells and their administration.
The possibility of combined therapy consisting of hyperbaric oxygen therapy and stem cell therapy is also an interesting approach. According to the experience from our centre, autologous cell therapy is an effective method with low rate of adverse events.